Scholay

学术搜索 · AI 审稿 · LaTeX 协作

Single-cell profiling reveals the trajectory of FOLR2-expressing tumor-associated macrophages to regulatory T cells in the progression of lung adenocarcinoma

作者:Chan Xiang, Min Zhang, Zhanxian Shang, Shengnan Chen, Jikai Zhao, Bowen Ding, Dong Jiang, Qian Zhu, Haohua Teng, Lei Zhu, Jinchen Shao, Ruiying Zhao, Min Ye, Yu Yang, Yuchen Han · 发表于:Cell Death and Disease · 年份:2023 · DOI:10.1038/s41419-023-06021-6 · 被引用次数:53 · 研究领域:Immune Cell Function and Interaction、Immune cells in cancer、Cancer Immunotherapy and Biomarkers

Abstract An immunosuppressive microenvironment enriched with regulatory CD4 + T lymphocytes (Tregs) facilitates the progression of lung adenocarcinoma (LUAD). This study aims to investigate the cellular mechanism underlying the formation of the immunosuppressive microenvironment in LUAD. LUAD samples ( n = 12) and normal lung samples ( n = 3) were obtained from patients with different pathological stages of LUAD. Single-cell RNA sequencing was performed to classify cellular components and analyze the transcriptomes, including transcription factors/targets and chemokine ligands/receptors, followed by bioinformatics study such as pseudotime analysis. Myeloid cells and T cells were the most abundant cell types in tumors and normal lung tissues, while tumor-associated macrophage-folate receptor 2 (TAM-FOLR2) and CD4 + nuclear receptor subfamily 4 group A member 3 (NR4A3) exhibited sharp increases in invasive adenocarcinoma (IA). The enrichment of TAM-FOLR2 in IA might result from alveolar resident macrophage-resistin (ARM-RETN) transformation and recruitment of dendritic cells (DCs) and other TAMs, as evidenced by temporal trajectories and differential expression profiles of chemokine ligands/receptors versus those in the early stages of tumors. High expression of CCL17/19/22 was observed in IA as well as in DCs, along with the strong interaction of TAM-FOLR2 with DCs. The results of pseudotime analysis suggested that CD4 + NR4A3 might potentially convert to CD4 + FOXP3, further ...